These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27133452)

  • 21. Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis
.
    Li Z; Sun M; Wang F; Shi J; Wang K
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):210-219. PubMed ID: 28025963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit.
    Ryder RE
    Diabet Med; 2015 Mar; 32(3):305-13. PubMed ID: 25472014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.
    Colmers IN; Bowker SL; Majumdar SR; Johnson JA
    CMAJ; 2012 Sep; 184(12):E675-83. PubMed ID: 22761478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
    Tseng CH
    J Formos Med Assoc; 2012 Mar; 111(3):123-31. PubMed ID: 22423665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.
    Piccinni C; Motola D; Marchesini G; Poluzzi E
    Diabetes Care; 2011 Jun; 34(6):1369-71. PubMed ID: 21515844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pioglitazone and bladder cancer: a propensity score matched cohort study.
    Wei L; MacDonald TM; Mackenzie IS
    Br J Clin Pharmacol; 2013 Jan; 75(1):254-9. PubMed ID: 22574756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No strong association is found between pioglitazone and bladder cancer.
    Wise J
    BMJ; 2015 Jul; 351():h3934. PubMed ID: 26202496
    [No Abstract]   [Full Text] [Related]  

  • 28. Pioglitazone and bladder cancer: a population-based study of Taiwanese.
    Tseng CH
    Diabetes Care; 2012 Feb; 35(2):278-80. PubMed ID: 22210574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use.
    Romero V; Peyton C; Gray I; Hemal A; Terlecki R
    BMC Urol; 2014 Jan; 14():10. PubMed ID: 24461081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pioglitazone and the risk of bladder cancer.
    Hillaire-Buys D; Faillie JL
    BMJ; 2012 May; 344():e3500. PubMed ID: 22653979
    [No Abstract]   [Full Text] [Related]  

  • 31. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.
    Turner RM; Kwok CS; Chen-Turner C; Maduakor CA; Singh S; Loke YK
    Br J Clin Pharmacol; 2014 Aug; 78(2):258-73. PubMed ID: 24325197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pioglitazone and bladder cancer: the pros and cons.
    Panikar V
    J Assoc Physicians India; 2012 Jan; 60():72-3. PubMed ID: 22715550
    [No Abstract]   [Full Text] [Related]  

  • 33. Meta-analysis confirms raised risk of bladder cancer from pioglitazone.
    Kermode-Scott B
    BMJ; 2012 Jul; 345():e4541. PubMed ID: 22763399
    [No Abstract]   [Full Text] [Related]  

  • 34. Pioglitazone Use and Risk of Bladder Cancer.
    Davies BJ
    JAMA; 2015 Dec; 314(23):2568. PubMed ID: 26670977
    [No Abstract]   [Full Text] [Related]  

  • 35. Pioglitazone Use and Risk of Bladder Cancer.
    Singh S; Suchard MA
    JAMA; 2015 Dec; 314(23):2567-8. PubMed ID: 26670976
    [No Abstract]   [Full Text] [Related]  

  • 36. Updated Review Confirms Potential Risk of Bladder Cancer with Pioglitazone.
    Aschenbrenner DS
    Am J Nurs; 2017 Apr; 117(4):25. PubMed ID: 28333739
    [No Abstract]   [Full Text] [Related]  

  • 37. Bladder cancer with pioglitazone: A case-control study.
    Malhotra B; Hiteshi P; Khalkho P; Malik R; Bhadada SK; Bhansali A; Shafiq N; Malhotra S; Kumar N; Rajput R; Rastogi A
    Diabetes Metab Syndr; 2022 Nov; 16(11):102637. PubMed ID: 36270237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pioglitazone Use and Risk of Bladder Cancer--Reply.
    Ferrara A; Lewis JD; Habel LA
    JAMA; 2015 Dec; 314(23):2568-9. PubMed ID: 26670978
    [No Abstract]   [Full Text] [Related]  

  • 39. The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
    Lee MY; Hsiao PJ; Yang YH; Lin KD; Shin SJ
    PLoS One; 2014; 9(1):e85479. PubMed ID: 24427312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study.
    Goyal A; Singh H; Sehgal VK; Jayanthi CR; Munshi R; Bairy KL; Kumar R; Kaushal S; Kakkar AK; Ambwani S; Goyal C; Mazumdar G; Adhikari A; Das N; Stephy DJ; Thangaraju P; Dhasmana DC; Rehman SU; Chakrabarti A; Bhandare B; Badyal DK; Kaur I; Chandrashekar K; Singh J; Dhamija P; Sarangi SC; Gupta YK
    Indian J Med Res; 2017 Oct; 146(4):468-475. PubMed ID: 29434060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.